2,3,7-Trichlor-6-methylamino-sulfonylchinoxalin | 18503-09-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,3,7-Trichlor-6-methylamino-sulfonylchinoxalin
• 英文别名: 2,3,7-trichloro-quinoxaline-6-sulfonic acid methylamide；2,3,7-trichloro-N-methylquinoxaline-6-sulfonamide
• CAS: 18503-09-8
• 化学式: C₉H₆Cl₃N₃O₂S
• 分子量: 326.591
• InChiKey: DWPNHOQMLHFCAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  80.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING
  申请人：Avedro, INC.

  公开号：EP2999471A1

  公开（公告）日：2016-03-30
• SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING TREATMENTS OF AN EYE
  申请人：Avedro, INC.

  公开号：EP3226871A1

  公开（公告）日：2017-10-11
• US20140343480A1
  申请人：——

  公开号：US20140343480A1

  公开（公告）日：2014-11-20
• Systems, Methods, and Compositions For Cross-Linking Treatments of an Eye
  申请人：Avedro, Inc.

  公开号：US20160175442A1

  公开（公告）日：2016-06-23

  Systems, methods, and compositions generate cross-linking activity for treatment of eye disorders. Various agents, additives, buffers, etc., may be employed in formulations with a cross-linking agent to enhance treatment. For example, a composition for applying treatment to a cornea of an eye includes a cross-linking agent that generates cross-linking activity in the cornea in response to exposure to a photo-activating light. The composition also includes an iron additive and citrate buffer. In some cases, the cross-linking agent may include riboflavin. In other cases, the iron additive may include FeSO 4 . In further cases, the iron additive may be dissolved in the citrate buffer.
• [EN] SYSTEMS, METHODS, AND COMPOSITIONS FOR CROSS-LINKING TREATMENTS OF AN EYE<br/>[FR] SYSTÈMES, PROCÉDÉS ET COMPOSITIONS POUR DES TRAITEMENTS DE RÉTICULATION D'UN ŒIL
  申请人：AVEDRO INC

  公开号：WO2016090016A1

  公开（公告）日：2016-06-09

  Systems, methods, and compositions generate cross-linking activity for treatment of eye disorders. Various agents, additives, buffers, etc., may be employed in formulations with a cross-linking agent to enhance treatment. For example, a composition for applying treatment to a cornea of an eye includes a cross-linking agent that generates cross-linking activity in the cornea in response to exposure to a photo-activating light. The composition also includes an iron additive and citrate buffer. In some cases, the cross-linking agent may include riboflavin. In other cases, the iron additive may include FeSO4. In further cases, the iron additive may be dissolved in the citrate buffer.